



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/751,056
Filing Date	January 2, 2004
First Named Inventor	Gerianne Tringali DiPiano
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	FEM 104



1 of 9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		3,921,636		Zaffaroni	11-25-1975	
		3,927,216		Witkowski, et al.	12-16-1975	
		4,081,533		Cheesman	03-28-1978	
		4,107,288		Oppenheim, et al.	08-15-1978	
		4,272,398		Jaffe	06-09-1981	
		4,286,587		Wong	09-01-1981	
		4,291,028		Vorys	09-22-1981	
		4,292,315		Vorys	09-29-1981	
		4,391,797		Folkman, et al.	07-05-1983	
		4,524,359		Champagne	06-18-1985	
		4,525,340		Lange, et al.	06-25-1985	
		4,588,724		Greenway, III, et al.	05-13-1986	
		4,591,496		Cohen, et al.,	05-27-1986	
		4,673,405		Guittard, et al.	06-16-1987	
		4,756,907		Beck, et al.	07-12-1988	
		4,762,717		Crowly, Jr.	08-09-1988	
		4,861,627		Mathiowitz, et al.	08-29-1989	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	0 501 056		Igarashi, et al.	09-02-1992		
		EP	0 566 135		Takeda Chemical Industries	10-20-1993		
		GB	767 824		Organon Labor Ltd.	02-06-1957		

Examiner's Signature		Date Considered	
-------------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/751,056
		Filing Date	January 2, 2004
		First Named Inventor	Gerianne Tringali DiPiano
		Group Art Unit	1628
		Examiner Name	Jennifer M. Kim
Sheet 2 of 9	Attorney Docket Number	FEM 104	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,873,092		Azuma, et al	10-10-1989	
		4,919,939		Baker	04-24-1990	
		4,965,128		Greidanus, et al.	10-23-1990	
		4,997,653		Igarashi, et al.	03-05-1991	
		5,057,317		Iida	10-15-1991	
		5,091,185		Castillo, et al.	02-25-1992	
		5,130,137		Crowley, Jr.	07-14-1992	
		5,145,684		Liversidge, et al.	09-08-1992	
		5,156,851		Castillo, et al.	10-20-1992	
		5,194,259		Soudant, et al.	03-16-1993	
		5,324,522		Krenning, et al.	06-28-1994	
		5,330,768		Park, et al.	07-19-1994	
		5,340,585		Pike, et al.	08-23-1994	
		5,359,030		Ekwuribe	10-25-1994	
		5,362,720		Labrie	11-08-1994	
		5,413,797		Khan, et al.	05-09-1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		PCT	WO 95/07071		Edko Trading and Representation Co.	03-16-1995		
		PCT	WO 95/31973		Eastman Kodak Co.	11-30-1995		
		PCT	WO 95/31974		Eastman Kodak Co.	11-30-1995		

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/751,056
				Filing Date	January 2, 2004
				First Named Inventor	Gerianne Tringali DiPiano
				Group Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	3	of	9	Attorney Docket Number	FEM 104

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,417,982		Modi	05-23-1995	
		5,434,146		Labrie	07-18-1995	
		5,438,040		Ekwuribe	08-01-1995	
		5,472,704		Santus, et al.	12-05-1995	
		5,482,925		Hutsell	01-09-1996	
		5,482,927		Maniar, et al.	01-09-1996	
		5,494,047		Van Os	02-27-1996	
		5,510,118		Bosch, et al.	04-23-1996	
		5,536,499		Znaiden, et al.	07-16-1996	
		5,552,160		Liversidge, et al.	09-03-1996	
		5,633,011		Dong, et al.	05-27-1997	
		5,643,604		Angeles Uribe, et al.	07-01-1997	
		5,651,976		Price, et al.	07-29-1997	
		5,705,170		Kong, et al.	01-06-1998	
		5,778,894		Dorogi, et al.	07-14-1998	
		5,789,442		Garfield, et al.	08-04-1998	
		5,843,509		Calvo Salve, et al.	12-01-1998	
		5,945,109		Schmidt, et al.	08-13-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		PCT	WO 96/00567		Eastman Kodak Co.	01-11-1996		
		PCT	WO 96/25150		Nanosystems LLC	08-22-1996		

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/751,056		
		Filing Date	January 2, 2004		
		First Named Inventor	Gerianne Tringali DiPiano		
		Group Art Unit	1628		
		Examiner Name	Jennifer M. Kim		
Sheet	4	of	9	Attorney Docket Number	FEM 104

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,071,526		Schmidt, et al.	06-06-2000	
		6,087,351		Nyce	07-11-2000	
		6,358,539		Murad	03-19-2002	
		6,436,428		Mahashabde, et al.	08-20-2002	
		6,517,864		Orup Jacobsen, et al	02-11-2003	
		6,743,441		Sanders, et al.	06-01-2004	
		6,908,623		Deaver, et al.	06-21-2005	
		2002/0150605		Yui, et al.	10-17-2002	
		2003/0109507		Franke, et al.	06-12-2003	
		2003/0143278		DiPiano, et al.	07-31-2003	
		2003/0175329		Azarnoff, et al.	09-18-2003	
		2004/0002503		Chang, et al.	01-01-2004	
		2005/0101579		Shippen	05-12-2005	
		2008/0153789		Dmowski, et al.	06-26-2008	
		2008/0299207		Martin	12-04-2008	
		12/497,865		DiPiano, et al.	07-06-2009	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		PCT	WO 96/37232		Universidade de Santiago de Compostela (ES)	11-28-1996		
		PCT	WO 98/11888		American Home Prod.	03-26-1998		
		PCT	WO 99/24041		Cellegy Pharma Inc.	05-20-1999		

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/751,056
				Filing Date	January 2, 2004
				First Named Inventor	Gerianne Tringali DiPiano
				Group Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	5	of	9	Attorney Docket Number	FEM 104

[illegible][illegible]

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/751,056
				Filing Date	January 2, 2004
				First Named Inventor	Gerianne Tringali DiPiano
				Group Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	6	of	9	Attorney Docket Number	FEM 104

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		AKIO, "Danazol Suppository", Patent Abstracts of Japan 15(263): (C-0847) (1991).	
		ANDERSON, et al., "Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group," <i>J. Urol.</i> 161: 1809-1812 (1999).	
		BARNHART, et al., "Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract", <i>Hum Reprod.</i> 16(6):1151-4 (2001).	
		BENITA, et al., "Characterization of drug-loaded poly(D,L-lactide) microspheres," <i>J Pharm Sci</i> 73(12): 1721-1724 (1984).	
		BRAUN, et al., "Effect of danazol <i>in vitro</i> and <i>in vivo</i> on monocyte-mediated enhancement of endometrial cell proliferation in women with endometriosis," <i>Fertility and Sterility</i> 62(1): 89-95 (1994).	
		BRENDLER, et al., "Topical oxybutynin chloride for relaxation of dysfunctional bladders," <i>J. Urol.</i> 141(6): 1350-52 (1989).	
		BUYSE, et al., "Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism," <i>J. Urol.</i> 160: 892-896 (1998).	
		CICINELLI, et al., "First uterine pass effect is observed when estradiol is placed in the upper buy not lower third of the vagina", <i>Fertility and Sterility</i> , 81(5):1414-1416 (2004).	
		COMER & GOA, "Extended-release oxybutynin," <i>Drugs Aging</i> 16: 149-155 (2000).	
		DAS NEVES, et al., "Gels as vaginal drug delivery systems", <i>Int. J. Pharm.</i> 2:318(1-2):1-14 (2006) Epub 2006 Mar 17.	
		DE ZIEGLER, et al., "Administration non-orale de la progestérone: Expériences et avenir de la voie transvaginale," <i>Rev. Med. Suisse Romande</i> pp. 13-28 (1994) (with English abstract).	
		FARQUHAR, et al., "Management of dysfunctional uterine bleeding," <i>Drugs</i> 44(4): 378-384 (1992).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/751,056		
		Filing Date	January 2, 2004		
		First Named Inventor	Gerianne Tringali DiPiano		
		Group Art Unit	1628		
		Examiner Name	Jennifer M. Kim		
Sheet	7	of	9	Attorney Docket Number	FEM 104

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FEMMEPHARMA, "FP1096-001 Executive Summary," (2004).	
		FINNIN and MORGAN, "Transdermal penetration enhancers: applications, limitations, and potential", <i>J. Pharm. Sci.</i> , 88(10):955-8 (1999).	
		GERAGHTY, et al., "The in vitro release of some antimuscarinic drugs from monoolein/water lyotropic crystalline gels," <i>Pharm. Res.</i> 13(8): 1265- 1271 (1996).	
		GOLDENBERG, "An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder," <i>Clin. Ther.</i> 21(4): 634-642 (1999).	
		GUPTA & SATHYAN, "Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin," <i>J. Clin. Pharmacol.</i> 39: 289-296 (1999).	
		GUERRIERO, et al., "Influence of vaginal danazol on uterine and brain perfusion during hormonal replacement therapy", <i>Menopause</i> , 8(6); 424-428 (2001) (abstract only).	
		HULL, et al., "Endometriosis: An enigmatic disease," <i>J Women's Health</i> 5(2): 111-120 (1996).	
		IGARASHI, "A new therapy for pelvic endometriosis and uterine adenomyosis: Local effect of vaginal and intrauterine danazol application," <i>Asia-Oceania J. Obstet. Gynaecol.</i> 16(1): 1-12 (1990).	
		LIM, et al., "Microencapsulation of living cells and tissues," <i>J Pharm. Sci.</i> 70(4): 351-354 (1981).	
		LIVERSIDGE, et al., "Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs", <i>Int J Pharm.</i> , 125:91-97 (1995).	
		LOBO, et al., "Vaginal route paradox: A direct transport to the uterus," <u>Symposium: The First Uterine Pass Effect</u> , Wyeth-Ayerst International, Inc. (1995).	
		MASSAD, et al., "The pharmacokinetics of intravesical and oral oxybutynin chloride," <i>J. Urol.</i> 148: 595-597 (1992).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/751,056		
		Filing Date	January 2, 2004		
		First Named Inventor	Gerianne Tringali DiPiano		
		Group Art Unit	1628		
		Examiner Name	Jennifer M. Kim		
Sheet	8	of	9	Attorney Docket Number	FEM 104

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MATHIOWITZ, et al., "Morphology of polyanhydride microsphere delivery system," <i>Scanning Microscopy</i> 4(2): 329-340 (1990).	
		MATHIOWITZ, et al., "Novel microcapsules for delivery systems," <i>Reactive Polymers</i> 6: 275-283 (1987).	
		MATHIOWITZ, et al., "Polyanhydride microspheres as drug carriers I. Hot-melt microencapsulation," <i>J Controlled Release</i> 5:13-22 (1987).	
		MATHIOWITZ, et al., "Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal," <i>J Appl. Polymer Sci.</i> 35: 755-774 (1988).	
		MIZUTANI, et al., "Danazol concentration in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository," <i>Fertility and Sterility</i> 63(6): 1184-1189 (1995).	
		Physicians' Desk Reference, Consult 1994 Supplements for Revisions, pp. 1372-1375.	
		RAMJEE, et al., "Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa", <i>AIDS Res Ther.</i> 4:20 pp.1-10 (2007).	
		SAITO, et al., "Treatment of overactive bladder with modified intravesical oxybutynin chloride," <i>Neurol. Urodyn.</i> 19: 683-688 (2000).	
		SALIB, et al., "Utilization of sodium alginate in drug microencapsulation," <i>Pharmazeutische Industrie</i> 40(11A): 1230-1234 (1978).	
		SCHRÖDER, et al., "Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder," <i>Urology</i> 56(6): 1063-1067 (2000).	
		SPOONER, Classification of Side Effects to Danazol Therapy, Winthrop Laboratories, Surrey, England.	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/751,056		
		Filing Date	January 2, 2004		
		First Named Inventor	Gerianne Tringali DiPiano		
		Group Art Unit	1628		
		Examiner Name	Jennifer M. Kim		
Sheet	9	of	9	Attorney Docket Number	FEM 104

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		"Sultrin," <u>Physicians' Desk Reference</u> , 51 st ed., pp. 1941 (1997).	
		TAKEBAYASHI, et al., "Danazol suspension injected into the uterine cervix of patients with adenomyosis and myoma. Preliminary study", <i>Gynecol. Obstet. Invest.</i> , 39(3):207-11 (1995) (abstract only).	
		"Terazol 7," <u>Physicians' Desk Reference</u> , 51 st ed., pp. 1943 (1997).	
		The First Uterine Pass Effect – A new finding for new options in progesterone therapy, West-Ayerst Internation, Inc., pp 1-2 (1995).	
		THÜROFF, et al., "Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo," <i>J. Urol.</i> 145: 813-816 (1991).	
		VERSI, et al., "Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence," <i>Obstet Gynecol.</i> 95(5): 718-721 (2000).	
		WAGNER, et al., "The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins", <i>Endocrinology</i> , 140(3):1449-58 (1999).	
		WELLBERY, et al., "Diagnosis and treatment of endometriosis", <i>Am. Fam. Physician</i> , 60:1753-68 (1999).	
		WOLTERS KLUWER HEALTH, INC., "Summary Review: Oxybutynin Chloride 10 % Gel", Wolthers Kluwer Health, Inc., (2009).	
		YAMASHITA, et al., "Immunohistochemical determination of endometrial progesterone receptor (PR) content after intrauterine infusion of danazol in rabbits", <i>Nippon Naibunpi Gakkai Zasshi</i> , 69(10):1044-1050 (1993) (abstract only).	
		ZHANG, et al., "Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones", <i>Bioorg. Med. Chem. Lett.</i> , 11(20):2747-50 (2001).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

